Palisade Bio (PALI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on next-generation, once-daily, oral PDE4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon.

• Lead product candidate, PALI-2108, targets inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

• Precision medicine approach using biomarker-based patient selection to improve clinical response rates.

Financial performance and metrics

• History of net operating losses and expects to continue incurring losses; has never generated revenue from product sales.

• Operations and development of PALI-2108 will require more capital than currently available.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for working capital and general corporate purposes, including R&D, vendor payables, hiring, and capital expenditures.